EZ Cap™ mCherry mRNA (5mCTP, ψUTP): Molecular Reporter mRNA with Cap 1 Structure and Enhanced Stability

Executive Summary: EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is a synthetic messenger RNA encoding the red fluorescent protein mCherry. It features a Cap 1 structure for improved translation efficiency (Guri-Lamce et al., 2024, DOI). Incorporated 5-methylcytidine triphosphate (5mCTP) and pseudouridine triphosphate (ψUTP) modifications suppress innate immune activation and improve mRNA stability (see product page: EZ Cap™ mCherry mRNA (5mCTP, ψUTP)). The mRNA is supplied at ~1 mg/mL in 1 mM sodium citrate buffer (pH 6.4), with a length of approximately 996 nucleotides. It is validated for robust fluorescent protein expression in reporter gene assays and cell component localization experiments. Storage at or below -40°C is required to maintain activity and stability.

Biological Rationale

mCherry is a monomeric red fluorescent protein derived from the Discosoma DsRed protein, widely used as a molecular and cellular marker (product page). Its emission maximum is approximately 610 nm, and its excitation maximum is around 587 nm, making it suitable for multiplexed imaging (More on mCherry wavelength). Reporter gene mRNAs such as EZ Cap™ mCherry mRNA allow for transient, non-integrating gene expression in cells. Cap 1 structures at the 5' end of mRNA are critical for efficient ribosome recruitment and for mimicking native mammalian mRNA, thereby enhancing translational output and reducing immunogenicity (Guri-Lamce et al., 2024, DOI). The addition of modified nucleotides, including 5mCTP and ψUTP, further suppresses recognition by innate immune sensors such as toll-like receptors (TLR7, TLR8), minimizing interferon responses and prolonging mRNA half-life both in vitro and in vivo.

Mechanism of Action of EZ Cap™ mCherry mRNA (5mCTP, ψUTP)

EZ Cap™ mCherry mRNA is synthesized with a Cap 1 structure using Vaccinia virus Capping Enzyme (VCE), GTP, S-adenosylmethionine (SAM), and 2´-O-Methyltransferase. The Cap 1 structure specifically involves methylation at the 2′-O position of the first nucleotide adjacent to the 5′ cap, which is known to enhance translation and facilitate immune evasion (Contrast: Mechanistic frontiers). Incorporation of 5mCTP and ψUTP into the mRNA backbone reduces detection by pattern recognition receptors (PRRs), thus lowering type I interferon induction and downstream inflammatory responses. The poly(A) tail supports efficient translation initiation and mRNA stability. These features allow for higher and more sustained expression of mCherry protein in transfected cells, as compared to unmodified or Cap 0 mRNAs.

Evidence & Benchmarks

• Cap 1 structures on mRNA significantly enhance translation and lower innate immune activation compared to Cap 0 mRNA (Guri-Lamce et al., 2024, DOI).
• 5mCTP and ψUTP modified mRNAs show increased stability and reduced immunostimulation in mammalian cells (see product documentation).
• Lipid nanoparticle (LNP) delivery of mRNA is compatible with Cap 1 and nucleotide-modified mRNAs, as validated for gene editing and reporter applications (Guri-Lamce et al., 2024, DOI).
• EZ Cap™ mCherry mRNA (5mCTP, ψUTP) outperforms unmodified mRNA in terms of fluorescent signal intensity and duration in standard transfection assays (Performance details).
• Storage at -40°C or below preserves mRNA integrity for at least 12 months under recommended buffer conditions (Stability benchmarks).

Applications, Limits & Misconceptions

EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is intended for use as a reporter gene in molecular biology, cell biology, and imaging experiments requiring transient expression of a red fluorescent marker. Typical applications include live-cell tracking, cell component localization, transfection optimization, and monitoring of delivery systems such as lipid nanoparticles (Experimental strategies guide). This article extends previous discussions by providing up-to-date evidence on immune evasion and stability benefits of Cap 1 and nucleotide modifications.

Common Pitfalls or Misconceptions

• Cap 1 and nucleotide modifications do not provide permanent expression; mRNA is transient and degraded over time.
• The product is not suitable for direct in vivo therapeutic use without compatible delivery systems (e.g., LNPs).
• mCherry mRNA does not integrate into the genome and cannot be used for stable cell line generation.
• Fluorescence intensity can be affected by transfection efficiency, cell type, and delivery method.
• Storage above -40°C may result in rapid mRNA degradation and loss of activity.

Workflow Integration & Parameters

EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is provided at ~1 mg/mL in 1 mM sodium citrate buffer, pH 6.4. For typical cell transfection assays, recommended working concentrations range from 0.1 to 1 μg mRNA per 10⁵ cells, depending on transfection reagent and cell type. Lipid nanoparticles (LNPs) and lipofection reagents (e.g., Lipofectamine MessengerMAX) are validated for efficient intracellular delivery (Guri-Lamce et al., 2024, DOI). For imaging purposes, mCherry fluorescence (excitation: 587 nm, emission: 610 nm) should be measured 8–48 hours post-transfection. The product should be kept at or below -40°C and thawed on ice prior to use. Avoid repeated freeze-thaw cycles to preserve integrity.

Conclusion & Outlook

EZ Cap™ mCherry mRNA (5mCTP, ψUTP) offers a robust, immune-evasive, and long-lived solution for fluorescent protein expression in molecular and cell biology research. Its Cap 1 structure and nucleotide modifications provide a significant advantage in terms of expression efficiency, stability, and low immunogenicity. Continued integration with advanced delivery platforms (e.g., LNPs) and multiplexed imaging workflows is expected to expand its utility for next-generation cell tracking and molecular diagnostics. For additional technical insights and application notes, see the official product page.